A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone
- PMID: 38587098
- DOI: 10.1002/bmc.5874
A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodone
Abstract
A sensitive and reliable LC-MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a sensitivity of 0.1 μg/L for all analytes. Sample preparation consisted of protein precipitation. Separation was performed on a Kinetix biphenyl column (2.1 × 100 mm, 1.7 μm), using ammonium formate 5 mm in 0.1% aqueous formic acid and methanol LC-MS grade 100% in gradient elution at a flow rate of 0.4 ml/min. Detection was performed in multiple reaction monitoring mode using positive electrospray ionization. The method was linear over the calibration range of 0.1-25.0 μg/L for oxycodone, noroxycodone and noroxymorphone and 0.1-5.0 μg/L for oxymorphone. The method demonstrated good performance in terms of intra- and interday accuracy (86.5-110.3%) and precision (CV 1.7-9.3%). The criteria for the matrix effect were met (CV < 15%) except for noroxymorphone, for which an additional method was applied to compensate for the matrix effect. Whole blood samples were stable for 4 h at room temperature. Plasma samples were stable for 24 h at room temperature and 3 months at -20°C. Furthermore, the method was successfully applied in a pharmacokinetic drug interaction study of oxycodone and enzalutamide in patients with prostate cancer.
Keywords: chromatography; drug monitoring; oxycodone; pharmacokinetics; tandem mass spectrometry.
© 2024 The Authors. Biomedical Chromatography published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Agema, B. C., Oosten, A. W., Sassen, S. D. T., Rietdijk, W. J. R., van der Rijt, C. C. D., Koch, B. C. P., Mathijssen, R. H. J., & Koolen, S. L. W. (2021). Population pharmacokinetics of oxycodone and metabolites in patients with cancer‐related pain. Cancers, 13(11), 2768. https://doi.org/10.3390/cancers13112768
-
- Detert Oude Weme, S. E. H., Hulskotte, L. M. G., Vervenne, W. L., Imholz, A. L. T., Cremers, R. G. H. M., Taxis, K. K., Reyners, A. K. L., van Berlo‐van de Laar, I. R. F., Jansman, F. G. A., & Benoist, G. E. (2023). Enzalutamide reduces oxycodone exposure in men with prostate cancer. Clinical Pharmacokinetics, 62, 989–996. https://doi.org/10.1007/s40262-023-01255-1
-
- European Medicines Agency. (2012). The EMA has published an updated guideline on the investigation of drug interactions. Reactions Weekly, 1410(1), 4. https://doi.org/10.2165/00128415-201214100-00010
-
- European Medicines Agency. (2022). Committee for medicinal products for human use. ICH guideline M10 on bioanalytical method validation and study sample analysis. (Publication No. EMA/CHMP/ICH/172948/2019).
-
- Gaudette, F., Sirhan‐Daneau, A., St‐Onge, M., Turgeon, J., & Michaud, V. (2016). Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography–tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 1008, 174–180. https://doi.org/10.1016/j.jchromb.2015.11.035
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
